- Home
- EVR vs MRNA Comparison
EVR vs MRNA Comparison
Compare EVR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVR
- MRNA
- Stock Information
- Founded
- EVR 1995
- MRNA 2010
- Country
- EVR United States
- MRNA United States
- Employees
- EVR N/A
- MRNA N/A
- Industry
- EVR Investment Managers
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVR Finance
- MRNA Health Care
- Exchange
- EVR Nasdaq
- MRNA Nasdaq
- Market Cap
- EVR 11.6B
- MRNA 9.8B
- IPO Year
- EVR 2006
- MRNA 2018
- Fundamental
- Price
- EVR $331.42
- MRNA $28.00
- Analyst Decision
- EVR Buy
- MRNA Hold
- Analyst Count
- EVR 8
- MRNA 17
- Target Price
- EVR $316.25
- MRNA $42.40
- AVG Volume (30 Days)
- EVR 454.2K
- MRNA 12.5M
- Earning Date
- EVR 10-22-2025
- MRNA 11-06-2025
- Dividend Yield
- EVR 1.02%
- MRNA N/A
- EPS Growth
- EVR 52.07
- MRNA N/A
- EPS
- EVR 11.01
- MRNA N/A
- Revenue
- EVR $3,238,871,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- EVR $18.25
- MRNA N/A
- Revenue Next Year
- EVR $22.87
- MRNA $9.75
- P/E Ratio
- EVR $29.88
- MRNA N/A
- Revenue Growth
- EVR 23.41
- MRNA N/A
- 52 Week Low
- EVR $148.63
- MRNA $23.15
- 52 Week High
- EVR $364.42
- MRNA $62.97
- Technical
- Relative Strength Index (RSI)
- EVR 48.71
- MRNA 60.22
- Support Level
- EVR $328.61
- MRNA $23.91
- Resistance Level
- EVR $339.04
- MRNA $28.99
- Average True Range (ATR)
- EVR 10.48
- MRNA 1.29
- MACD
- EVR -3.39
- MRNA 0.47
- Stochastic Oscillator
- EVR 28.23
- MRNA 79.63
About EVR Evercore Inc.
Evercore Inc is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,380 employees at the end of 2024, and about 75% of its revenue is derived from the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.